StockNews.AI
GSK
StockNews.AI
27 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

1. Pomerantz LLP investigates potential securities fraud by GSK and its executives. 2. GSK's Blenrep opioid was rejected by FDA's advisory committee on proposed dosage. 3. Following the FDA news, GSK's ADR price fell 4.73% to $36.47. 4. Investors are encouraged to join the class action against GSK. 5. Pomerantz is known for securities class action lawsuits and corporate misconduct.

3m saved
Insight
Article

FAQ

Why Bearish?

GSK's negative FDA feedback indicates potential risks affecting its stock value. Historical cases show FDA setbacks often lead to significant drops in biotech stocks, negatively impacting investor sentiment.

How important is it?

The investigation and FDA's negative decision could increase regulatory scrutiny, impacting investor confidence. The news directly relates to GSK's stock performance and potential legal ramifications.

Why Short Term?

The immediate market reaction to the FDA news shows short-term impacts. Ongoing investigations could influence GSK's reputation and stock volatility in the near future.

Related Companies

BMYMRNAJNJ
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On July 17, 2025, GSK issued a press release announcing “that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.”  On this news, GSK’s American Depositary Receipt (“ADR”) price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.  CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News